INZY
Inozyme Pharma, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website inozyme.com
- Employees(FY) 56
- ISIN US45790W1080
Performance
-1.08%
1W
-5.15%
1M
-20.96%
3M
+42.86%
6M
+7.98%
YTD
-30.83%
1Y
Profile
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Technical Analysis of INZY 2024-05-10
Overview:
In analyzing the technical indicators for INZY stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key indicators, we aim to offer valuable insights and recommendations for potential inves...
Recent News & Updates
- 2024-05-07 20:30
- 2024-05-07 01:52
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024(Investorplace)
- 2024-05-06 20:30
- 2024-05-02 20:30
- 2024-04-07 18:30
- 2024-04-05 06:00
- 2024-04-01 20:30
- 2024-03-26 08:30
- 2024-03-25 20:30
- 2024-03-12 08:30
- 2024-03-11 20:30
- 2024-02-26 08:30
- 2024-02-25 19:30
- 2024-02-06 08:30
- 2024-02-05 19:30
- 2023-12-04 19:30
- 2023-11-08 19:30
- 2023-11-06 19:30
- 2023-11-03 04:15
- 2023-10-25 20:30
- 2023-10-14 00:07
10 Stocks With Huge Catalysts on the Way(Yahoo Finance)
- 2023-10-10 00:00
- 2023-10-09 20:30
- 2023-10-05 20:30
- 2023-09-25 19:30
- 2023-09-19 20:30
- 2023-09-05 20:30
- 2023-09-04 20:30
- 2023-08-07 20:30
- 2023-08-06 22:50
Page 1 of 4
previousnext